Amyloid Oligomers (A11) Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, IHC, IP, ICC |
---|---|
Primary Accession | P05067 |
Other Accession | NM_000484.2 |
Host | Rabbit |
Reactivity | Human, Eukaryote, Mouse, Rat |
Clonality | Polyclonal |
Description | Rabbit Anti-Human Amyloid Oligomers (A11) Polyclonal |
Target/Specificity | Recognizes all types of amyloid oligomers. Appears to recognize a peptide backbone epitope that is common to amyloid oligomers, but is not found in native proteins, amyloidogenic monomer or mature amyloid fibrils. |
Other Names | Amyloid Oligomer alpha beta Antibody, A11 Antibody, Amyloid Oligomer AlphaBeta Antibody, APP Antibody |
Immunogen | Synthetic molecular mimic of soluble oligomers |
Purification | Protein A Purified |
Storage | -20ºC |
Storage Buffer | PBS, 50% glycerol, 0.09% sodium azide |
Shipping Temperature | Blue Ice or 4ºC |
Certificate of Analysis | A 1:1000 dilution of SPC-506 was sufficient for detection of amyloid oligomers in 10 µg of mouse brain lysates by colorimetric immunoblot analysis using Goat anti-rabbit IgG:HRP as the secondary antibody. |
Cellular Localization | Membrane |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Amyloid monomeric proteins can sometimes oligomerize into destructive amyloid fibrils. Amyloidogenic conformations of non-disease related proteins can be created by partial protein misfolding or denaturation. Many degenerative diseases are known to be related to the accumulation of misfolded proteins as amyloid fibres (1, 2). These include the amyloid-β peptide plaques and tau neurofibrillary tangles in senile plaques of Alzheimer’s symptomology, the deposition of α-synuclein in the Lewy bodies of Parkinson’s disease, and accumulation of polyglutamine-containing aggregates in Huntington’s disease (2, 3).
References
1. Glabe C.G. (2004) Trends Biochem Sci. 29(10): 542-547.
2. Kayed R., et al. (2004) J Bio. Chem. 279: 46363-46366.
3. Kayed R., et al. (2003) Science. 300(5618): 486-489.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.